Diagnosis and evaluation of serum midkine levels in response to TACE treatment in patients with hepatocellular carcinoma

Abstract

Abstract: Objective To analyze the level of serum medium-term factor (MK) in diagnosing and evaluating the response to TACE treatment in HCC patients.Methods 40 HCC patients scheduled to receive TACE treatment and 30 normal healthy subjects were prospectively collected from Wuxi No.9 Institute Affiliated to Suzhou University between January 2020 and May 2022, The serum MK concentration was determined by ELISA. The HCC patients treated with TACE were divided into effective group and ineffective group based on RECIST criteria. Serum MK levels were compared between groups and HCC patients before and after treatment. Results 18 cases were effective and 22 cases were ineffective. The serum MK level in the HCC group before treatment was 740.9 (456.2, 933.3) ng/L, which was significantly higher than that of the normal group [164.5 (114.9, 200.3) ng/L, Z=6.415, P<0.001]. The curative effect of liver cancer group was analyzed. In the effective group, the serum MK level before treatment was 570.0 (280.0, 782.3) ng/L, and the serum MK after treatment was 147.5 (103.4, 213.5) ng/L. In the ineffective group, the serum MK level before treatment was 899.9 (676.1, 1213.0) ng/L, and 469.0 (300.0, 837.5) ng/L after treatment. There were significant differences in serum MK levels between the effective group and the ineffective group before and after treatment (before treatment: Z=2.990, P=0.003; After treatment: Z=4.758, P<0.001). The median decrease of serum MK before and after treatment in the effective group was 361.0 (136.3, 648.6) ng/L, while it was 354.9 (238.9, 516.3) ng/L in the ineffective group. There was no significant difference between the two groups (Z=0.068, P>0.05). Conclusion The level of serum MK has diagnostic and evaluative value in assessing the response to TACE in HCC patients.

Key words: Hepatocellular carcinoma, Transcatheter arterial chemoembolization, Midkine

WANG Kai-li, HU Xiao-wei, YIN Jian, LIU Qing-yang, WANG Qiu-bo. Diagnosis and evaluation of serum midkine levels in response to TACE treatment in patients with hepatocellular carcinoma[J]. Chinese Hepatolgy, 2023, 28(9): 1072-1074.

References

[1] Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol,2017,34(2):153-159.
[2] Sim HW, Knox J. Hepatocellular carcinoma in the era of immunotherapy. Curr Probl Cancer,2018,42(1):40-48.
[3] Lee KH, Sung KB, Lee DY, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma: anatomic and hemodynamic considerations in the hepatic artery and portal vein. Radiographics,2002,22(5):1077-1091.
[4] Chang KT, Liu CJ, Tsai HT, et al. Effects and safety of body positioning on back pain after transcatheter arterial chemoembolization in people with hepatocellular carcinoma: A randomized controlled study. Int J Nurs Stud,2020,109:103641.
[5] Gunji T, Kawauchi N, Akahane M, et al. Long-term outcomes of transcatheter arterial chemoembolization with autologous blood clot for unresectable hepatocellular carcinoma. Int J Oncol.2002,21(2):427-432.
[6] 吴水天. CT增强扫描在评估原发性肝细胞肝癌TACE术后疗效中的应用. 中国CT和MRI杂志,2022,20(3):91-93.
[7] Sato Y, Watanabe H, Sone M, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci,2013,118(1):16-22.
[8] Zhang ZZ, Wang G, Yin SH, et al. Midkine: A multifaceted driver of atherosclerosis. Clin Chim Acta,2021,521:251-257.
[9] Campbell VK, Gately RP, Krishnasamy R, et al. Midkine and chronic kidney disease-associated multisystem organ dysfunctions. Nephrol Dial Transplant,2021,36(9):1577-1584.
[10] Tsuchiya N, Sawada Y, Endo I, et al. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol,2015,21(37):10573-10583.
[11] Lu Q, Li J, Cao H, et al. Comparison of diagnostic accuracy of Midkine and AFP for detecting hepatocellular carcinoma: a systematic review and meta-analysis. Biosci Rep,2020,40(3): BSR20192424.
[12] Zhu WW, Guo JJ, Guo L, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res,2013,19(14):3944-3954.
[13] 乔敏, 赵一鉴, 张建巧, 等. TACE联合射频消融治疗原发性肝癌患者疗效研究. 实用肝脏病杂志,2021,24(1):119-122.
[14] Zheng L, Li H, Huang J, et al. Serum midkine levels for the diagnosis and assessment of response to interventional therapy in patients with hepatocellular carcinoma. J Interv Med,2020,4(1):39-45.

[1]	GE Shu, LIU Yang-yang. Contrast-enhanced ultrasonography and enhanced CT in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(9): 1075-1078.
[2]	ZHANG Xiang, LI Ying-ying, TANG Qing, LI Wei, SUN Li-zhu. Evaluation value of CD8⁺ T lymphocyte level in immunotherapy efficacy in patients with advanced hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(9): 1084-1087.
[3]	NIE Bin, ZHAO Tie-jun, ZHANG Sheng-long. A prognostic analysis on the radical resection of primary hepatocellular carcinoma with microvascular invasion by different resection margin schemes [J]. Chinese Hepatolgy, 2023, 28(8): 921-923.
[4]	WANG Chun-hong, FENG Wei-wei, ZHANG Jing, SI Chen-fei. A clinical study for the therapeutic effect of arotinib on patients with stage III primary liver cancer after interventional therapy [J]. Chinese Hepatolgy, 2023, 28(8): 928-931.
[5]	HU Zhi-qiang, MEN Fen-yong, LIU Dong. A correlation analysis between immune-related adverse events and the curative effect caused by immune checkpoint inhibitors on patients with advanced primary Hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(8): 935-937.
[6]	XU Jia-pin, SHAO Chun-yan, LIU Di-fa, XU Ya-chun. The value of diffusion weighted imaging of voxel incoherent motion in predicting microvascular invasion and evaluating the efficacy of TACE therapy on hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(8): 938-942.
[7]	YUAN Qing-gong, ZHANG Yan, LI Jun-hui, YANG Wen-bin. Effect of fibronectin type III domain containing 5 on the metastatic activity of HepG2 hepatoma cells in vitro and its mechanism [J]. Chinese Hepatolgy, 2023, 28(8): 943-946.
[8]	HUANG Qian, LI Ya-nan, ZENG Da-wu. Expression and prognostic value of ANLN, CYP2C9 and HMMR in hepatitis B virus-associated hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(7): 775-780.
[9]	LI Gang, CAO Zhi-qun, NIU Shuai. Effect of TACE on serum tumor markers and recurrence risk after radical hepatocellular carcinoma resection at different time [J]. Chinese Hepatolgy, 2023, 28(7): 781-784.
[10]	CHEN Yong-ying, PENG Pan, XU Lei-lei. Application of SVM prediction model in judging the degree of pathological differentiation of primary hliver cancerepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(7): 785-788.
[11]	YANG Ya-meng, LUO Dan-feng. The inhibitory effects of mTOR inhibitor combined with ursodeoxycholic acid on the growth, immune escape, and Ras/ERK signaling pathway of hepatocellular carcinoma in rats [J]. Chinese Hepatolgy, 2023, 28(7): 789-793.
[12]	GUO Dan-dan, QIN Ling, GAO Weng-feng, YUAN Chun-wang, ZHANG Ying-hua, ZHANG Yong-hong. Correlation between the plasma levels of interleukin-33 and hepatocellular carcinoma, thermal ablation therapy [J]. Chinese Hepatolgy, 2023, 28(6): 665-667.
[13]	MA Bo-heng, WANG Xia, WU Ying. An evaluation of serum biochemical indexes, pathological characteristics and surgical treatment efficacy of sarcomatoid hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(6): 676-679.
[14]	JIN Zhi-en, XU pan, YUAN Hong-wei, XU Jing-jiang. A comparison between HCV-related hepatocellular carcinoma patients with or without direct acting antivirals treatment [J]. Chinese Hepatolgy, 2023, 28(6): 680-682.
[15]	QIAN Hou-long, LI Yang, ZHU Xiang, LU Kui. The efficacy and safety of carrilizumab combined with ramvaritinib in the treatment of unresectable hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(4): 452-456.